Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | Subsequent Events On July 7, 2025, the Company closed the July 2025 Offering relating to the issuance and sale by the Company of 14,285,715 shares of the Company’s common stock, par value $0.001 per share, and accompanying 2025 Warrants, at a combined public offering price of $1.75 per share of Common Stock and accompanying 2025 Warrants. The net proceeds to the Company from the July 2025 Offering were $22.5 million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. All of the shares and accompanying 2025 Warrants were sold by the Company. In July 2025, the 2,135,477 Pre-Funded Warrants issued in the April 2024 Offering (see “Liquidity” in Note 2) were exercised in full, with proceeds to the Company of $2,000. On August 1, 2025 the Company and GeneOne entered into a Settlement Agreement to settle all claims by and between them.
|